Michael Böhm Selected Research

Systolic Heart Failure

1/2021	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
1/2020	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.
10/2017	Heart rate and its reduction in chronic heart failure and beyond.
1/2017	Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.
1/2017	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
12/2016	Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
9/2016	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
6/2016	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
2/2016	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
1/2016	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Böhm Research Topics

Disease

223	Heart Failure 08/2022 - 02/2002
146	Hypertension (High Blood Pressure) 06/2022 - 01/2002
43	Atrial Fibrillation 06/2022 - 06/2003
42	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 02/2002
39	Myocardial Infarction 04/2022 - 06/2002
39	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 03/2002
33	Fibrosis (Cirrhosis) 02/2022 - 02/2002
31	Systolic Heart Failure 01/2021 - 11/2007
30	Atherosclerosis 01/2021 - 12/2002
22	Inflammation (Inflammations) 02/2022 - 07/2002
22	Stroke (Strokes) 01/2022 - 06/2002
22	Cardiogenic Shock 01/2021 - 08/2007
18	Left Ventricular Dysfunction 04/2022 - 02/2002
17	Cardiomyopathies (Cardiomyopathy) 01/2022 - 10/2002
16	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2008
15	Hypertrophy 01/2022 - 09/2002
15	Shock 01/2021 - 03/2004
12	Chronic Renal Insufficiency 02/2022 - 08/2013
11	Cardiomegaly (Heart Hypertrophy) 01/2013 - 02/2002
10	Diabetes Mellitus 01/2018 - 10/2008
9	Vascular Diseases (Vascular Disease) 01/2021 - 08/2006
9	Coronary Disease (Coronary Heart Disease) 10/2017 - 03/2002
9	Acute Coronary Syndrome 03/2017 - 02/2002
8	Heart Diseases (Heart Disease) 06/2022 - 09/2002
8	Hypotension (Low Blood Pressure) 01/2022 - 07/2010
8	Hemorrhage 01/2021 - 01/2008
8	Infarction (Infarctions) 01/2021 - 02/2002
8	Thrombosis (Thrombus) 10/2020 - 02/2003
8	Erectile Dysfunction 01/2016 - 05/2003
7	Body Weight (Weight, Body) 01/2019 - 09/2002
7	Myocarditis (Carditis) 01/2019 - 01/2003
6	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2009
6	Dyslipidemias (Dyslipidemia) 01/2022 - 08/2009
6	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2008
6	Ventricular Remodeling 01/2021 - 12/2004
6	Atherosclerotic Plaque (Atheroma) 01/2020 - 05/2008
6	Bradycardia 12/2016 - 09/2009
6	Essential Hypertension 01/2016 - 01/2004
6	Peripheral Arterial Disease 12/2015 - 03/2007
5	COVID-19 05/2022 - 12/2020
5	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2021 - 02/2002

Drug/Important Bio-Agent (IBA)

45	IvabradineIBA 01/2019 - 01/2007
35	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 02/2002
33	Antihypertensive Agents (Antihypertensives)IBA 06/2022 - 09/2010
23	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 01/2002
20	DiureticsIBA 06/2022 - 06/2003
20	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2004
20	Pharmaceutical PreparationsIBA 01/2022 - 06/2004
20	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 10/2007
18	Ramipril (Altace)FDA LinkGeneric 01/2021 - 02/2002
16	salicylhydroxamic acid (SHAM)IBA 06/2022 - 03/2002
16	Telmisartan (Micardis)FDA Link 01/2021 - 09/2006
16	CholesterolIBA 12/2019 - 06/2002
14	empagliflozinIBA 01/2022 - 01/2019
12	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2002
12	Rosuvastatin Calcium (Crestor)FDA Link 06/2014 - 06/2002
11	dapagliflozinIBA 01/2022 - 11/2019
11	LipidsIBA 01/2021 - 03/2002
10	CreatinineIBA 01/2022 - 11/2005
10	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 06/2009
10	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2020 - 04/2007
10	pro-brain natriuretic peptide (1-76)IBA 01/2020 - 05/2006
10	CollagenIBA 01/2020 - 03/2007
10	Nebivolol FDA Link 01/2015 - 11/2002
9	SodiumIBA 04/2022 - 12/2012
9	Messenger RNA (mRNA)IBA 01/2020 - 05/2002
9	Indicators and Reagents (Reagents)IBA 10/2017 - 04/2009
9	Angiotensin IIIBA 06/2010 - 03/2002
8	Angiotensin Receptor AntagonistsIBA 01/2022 - 01/2002
8	Sodium-Glucose Transport ProteinsIBA 01/2022 - 11/2019
8	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021 - 04/2002
8	Natriuretic PeptidesIBA 03/2021 - 01/2015
8	ReninIBA 01/2021 - 02/2002
8	AldosteroneIBA 10/2016 - 03/2002
7	Eplerenone (Inspra)FDA LinkGeneric 04/2022 - 07/2010
7	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 04/2010
7	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 11/2019
7	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2022 - 09/2010
7	Neprilysin (Neutral Endopeptidase)IBA 01/2022 - 01/2015
7	Paclitaxel (Taxol)FDA LinkGeneric 10/2020 - 10/2003
7	aliskiren FDA Link 01/2018 - 11/2010
7	Adrenergic Agents (Adrenergic Drugs)IBA 05/2013 - 03/2002
7	erucylphosphocholineIBA 05/2011 - 01/2004
6	Apolipoproteins E (ApoE)IBA 01/2016 - 10/2006
6	Interleukin-6 (Interleukin 6)IBA 07/2015 - 02/2002
6	C-Reactive ProteinIBA 08/2014 - 02/2002
6	Atrial Natriuretic Factor (ANF)IBA 03/2013 - 03/2002
5	omega-Chloroacetophenone (Mace)IBA 04/2022 - 10/2008

Therapy/Procedure

137	Therapeutics 08/2022 - 01/2002
97	Denervation 06/2022 - 12/2010
45	Catheters 06/2022 - 05/2009
40	Sympathectomy (Sympathectomies) 01/2021 - 12/2010
11	Stents 07/2020 - 04/2003
10	Drug Therapy (Chemotherapy) 02/2022 - 08/2007
10	Patient Readmission 01/2022 - 06/2009
9	Heart Transplantation (Grafting, Heart) 11/2021 - 08/2008
9	Percutaneous Coronary Intervention 01/2021 - 01/2008
6	Secondary Prevention 02/2019 - 04/2003
6	Aftercare (After-Treatment) 12/2016 - 09/2006
5	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 10/2002